Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M |
| Total Depreciation and Amortization | 97.00K | 99.00K | 99.00K | 133.00K | 78.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.87M | 3.26M | 4.59M | 3.41M | 1.34M |
| Change in Net Operating Assets | 12.48M | 2.86M | 3.05M | -1.66M | -422.00K |
| Cash from Operations | -46.98M | -30.56M | -23.89M | -27.63M | -27.44M |
| Capital Expenditure | -138.00K | -5.00K | -46.00K | -24.00K | -31.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.34M | -201.27M | 26.49M | 14.82M | -23.08M |
| Cash from Investing | 37.20M | -201.28M | 26.45M | 14.79M | -23.11M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.08M | 274.69M | 568.00K | 161.00K | 39.68M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -192.00K | -172.00K | -- | -- | 0.00 |
| Cash from Financing | 4.88M | 274.51M | 568.00K | 161.00K | 39.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.90M | 42.68M | 3.12M | -12.68M | -10.88M |